Evidence map›Paper›PMID 31181219›Full record

ArticleJournal of virological methods2019

Performance of InBios ZIKV Detect™ 2.0 IgM Capture ELISA in two reference laboratories compared to the original ZIKV Detect™ IgM Capture ELISA.

Alison Jane Basile, Jingning Ao, Kalanthe Horiuchi, Vera Semenova, Evelene Steward-Clark, Jarad Schiffer

Abstract readComparative Study
In one paragraph

Article in Journal of virological methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Evidence of Ongoing Transmission of Zika Virus in Mérida, Mexico.The American journal of tropical medicine and hygiene · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Zika Virus Envelope Protein Domain III Produced inDiagnostics (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alison Jane BasileDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, United States. Electronic address: ajj1@cdc.gov.
Jingning AoMicrobial Pathogenesis and Immune Response Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Kalanthe HoriuchiDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, United States.
Vera SemenovaMicrobial Pathogenesis and Immune Response Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Evelene Steward-ClarkMicrobial Pathogenesis and Immune Response Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jarad SchifferMicrobial Pathogenesis and Immune Response Laboratory, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

ZIKV Detect™ 2.0 IgM Capture ELISA (InBios International, Seattle, WA) recently replaced the ZIKV Detect™ IgM Capture ELISA and a number of significant changes have been made to the original version. This study compares data generated from the ZIKV Detect™ 2.0 IgM Capture ELISA, to data generated using the original version of the kit. The same sample sets were used in this comparison, and reference test results for these samples were used to assess sensitivity, specificity, accuracy and concordance of results across two laboratories. Average sensitivity increased from 90.4% to 92.5% with the updated kit where the increase was not statistically different, and specificity increased from 79.5% to 97.4%, a statistically-significant difference. Accuracy of the ZIKV Detect™ 2.0 IgM Capture ELISA was 89% compared to 63.9% for the original version of the kit, and agreement across the laboratories increased from 79.5% to 97.4%. With secondary dengue virus infections, specificity increased from 9.3% to 82.6% with the updated kit, primarily due to the change in interpretation criteria that no longer includes "Possible Zika positive."

Indexed as

Antibodies, ViralClinical Laboratory TechniquesEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin MReagent Kits, DiagnosticReference StandardsSensitivity and SpecificityZika VirusZika Virus InfectionAntibodies, ViralImmunoglobulin MReagent Kits, DiagnosticELISAIgMInBiosVersion 2.0Zika

Identifiers

PMID31181219
PMCPMC7176032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.